Efinopegdutide record · updated 18h ago

Metabolic & appetiteGrade A · human clinicalResearch use only

All 1 studies Jump to the evidence Compare

What is Efinopegdutide used for?

Research peptide discovered via AI researcher. peptide-based therapeutic

How it works: GLP-1/GIP receptor agonist

Primarily researched for · Metabolic & appetite

Development stage

where Efinopegdutide sits between preclinical work and regulatory approval

1Current
Preclinical
Animal / in-vitro work
2Not reached
Phase 1
Safety in humans
3Not reached
Phase 2
Efficacy signal
4Not reached
Phase 3
Confirmatory trials
5Not reached
Approved
Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 10 registered trials. It describes the research record, not a recommendation.

Identity

NameEfinopegdutide

Chain length—

Molecular weight—

Formula—

Structure type—

ClassMetabolic

Research levelEmerging

Discovered byThe Librarian · 2026

Pharmacology

MechanismGLP-1/GIP receptor agonist

Route—

Half-life—

Time to peak—

Duration—

Extraction confidence0.70

Effect profile · 0–5

These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Oct 6, 2026. How this works →

Research stats

Total studies1

Human / animal / cellular0 / 0 / 0

Highest trial phase—

Years covered2025

Latest study12d ago

Publication history

20252025

Research funding

—no NIH grants found

Safety signals

FAERS reportsnone recorded

Serious AEs in animal work—

Community reports—

Positive —Neutral —Negative —

Records

ChEMBL ClinicalTrials.gov DrugBank Google Scholar PubChem PubMed · 1 Semantic Scholar UniProt

Study register

1 rowOpen in the library →

Study	Type	Year	Summary depth
Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis. Finding5.21% reduction in liver fat content after 24 weeks, n=2600.	review	2025	Full text read0.90

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Efinopegdutide will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Efinopegdutide is discussed should be drawn from it.